 |
13 Diseases |  |
52 Trials |
|
52 Trials |  |
3235 News |  |
| «12...25262728293031323334353637 |
- | Alecensa (alectinib) / Roche
Trial completion: A Cross-over Study Examining the Bioequivalence of 3 Test Formulations to a Reference Formulation of Alectinib (RO5424802) in Healthy Volunteers (clinicaltrials.gov) - Aug 21, 2014
P1, N=49, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed
- | Alecensa (alectinib) / Roche
Trial completion: A Study Investigating the Effect of Food and Esomeprazole on the Single Oral Dose Pharmacokinetics of Alectinib (RO5424802) in Healthy Volunteers. (clinicaltrials.gov) - Aug 21, 2014
P1, N=42, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Not yet recruiting --> Completed
- ||| Alecensa (alectinib) / Roche
Enrollment closed, Enrollment change: A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Aug 15, 2014
P2, N=114, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Completed Recruiting --> Active, not recruiting | N=85 --> 114
- Alecensa (alectinib) / Roche
Trial termination: A Study of the Elimination, Pharmacokinetics, and Metabolism of RO5424802 (clinicaltrials.gov) - Aug 12, 2014
P1, N=6, Terminated, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | N=85 --> 114 Completed --> Terminated
- || Trial primary completion date, Tumor mutational burden, PD(L)-1 Biomarker, Metastases: My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Jul 23, 2014
P2a, N=500, Recruiting, Sponsor: Genentech
Completed --> Terminated Trial primary completion date: Aug 2019 --> Jan 2020
- |||||| Alecensa (alectinib) / Roche
Enrollment open, Metastases: ALEX: A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants (clinicaltrials.gov) - Jul 23, 2014
P3, N=286, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Aug 2019 --> Jan 2020 Not yet recruiting --> Recruiting
- |||| Alecensa (alectinib) / Roche
Trial primary completion date, Metastases: ALEX: A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants (clinicaltrials.gov) - Jul 1, 2014
P3, N=286, Not yet recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2018 --> Dec 2017
- || Trial primary completion date, Tumor mutational burden, PD(L)-1 Biomarker, Metastases: My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors (clinicaltrials.gov) - May 18, 2014
P2a, N=500, Recruiting, Sponsor: Genentech
Trial primary completion date: Apr 2018 --> Dec 2017 Trial primary completion date: Jan 2020 --> Aug 2019
- || Trial completion date, Tumor mutational burden, PD(L)-1 Biomarker, Metastases: My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors (clinicaltrials.gov) - May 18, 2014
P2a, N=500, Recruiting, Sponsor: Genentech
Trial primary completion date: Jan 2020 --> Aug 2019 Trial completion date: Jan 2020 --> Aug 2019
- Alecensa (alectinib) / Roche
Trial completion date: A Cross-over Study Examining the Bioequivalence of 3 Test Formulations to a Reference Formulation of Alectinib (RO5424802) in Healthy Volunteers (clinicaltrials.gov) - May 7, 2014
P1, N=49, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Jan 2020 --> Aug 2019 Trial completion date: Jun 2014 --> May 2014
- Alecensa (alectinib) / Roche
Enrollment change: A Cross-over Study Examining the Bioequivalence of 3 Test Formulations to a Reference Formulation of Alectinib (RO5424802) in Healthy Volunteers (clinicaltrials.gov) - May 7, 2014
P1, N=49, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Jun 2014 --> May 2014 N=40 --> 49
- Alecensa (alectinib) / Roche
Enrollment closed: A Cross-over Study Examining the Bioequivalence of 3 Test Formulations to a Reference Formulation of Alectinib (RO5424802) in Healthy Volunteers (clinicaltrials.gov) - May 7, 2014
P1, N=49, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=40 --> 49 Not yet recruiting --> Active, not recruiting
- ||| Alecensa (alectinib) / Roche
Trial initiation date: A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment (clinicaltrials.gov) - May 4, 2014
P2, N=130, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Active, not recruiting Initiation date: Aug 2013 --> Jun 2013
- ||| Alecensa (alectinib) / Roche
Trial initiation date: A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Apr 21, 2014
P2, N=85, Recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Aug 2013 --> Jun 2013 Initiation date: Sep 2013 --> Apr 2013
- ||| Trial initiation date, Tumor mutational burden, PD(L)-1 Biomarker, Metastases: My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Apr 15, 2014
P2a, N=500, Recruiting, Sponsor: Genentech
Initiation date: Sep 2013 --> Apr 2013 Initiation date: Mar 2014 --> Apr 2014
- |||| Enrollment open, Tumor mutational burden, PD(L)-1 Biomarker, Metastases: My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Apr 6, 2014
P2a, N=500, Recruiting, Sponsor: Genentech
Initiation date: Mar 2014 --> Apr 2014 Not yet recruiting --> Recruiting
- Tecentriq (atezolizumab) / Roche, Alecensa (alectinib) / Roche
Enrollment open, Combination therapy, PD(L)-1 Biomarker, Metastases: A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Mar 30, 2014
P1, N=32, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| New P2a trial, Tumor mutational burden, PD(L)-1 Biomarker, Metastases: My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Mar 17, 2014
P2a, N=500, Recruiting, Sponsor: Genentech
- | Alecensa (alectinib) / Roche
Trial completion: A Study of the Effects of Posaconazole on Alectinib (RO5424802) Pharmacokinetics in Healthy Volunteers (clinicaltrials.gov) - Mar 13, 2014
P1, N=23, Completed, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||||||| Alecensa (alectinib) / Roche
New P3 trial, Metastases: ALEX: A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants (clinicaltrials.gov) - Feb 27, 2014
P3, N=286, Not yet recruiting, Sponsor: Hoffmann-La Roche
- | Alecensa (alectinib) / Roche
New P1 trial: A Cross-over Study Examining the Bioequivalence of 3 Test Formulations to a Reference Formulation of Alectinib (RO5424802) in Healthy Volunteers (clinicaltrials.gov) - Feb 26, 2014
P1, N=40, Not yet recruiting, Sponsor: Hoffmann-La Roche
- | Alecensa (alectinib) / Roche
Trial completion: A Study of the Effect of Multiple Doses of Rifampin on the Single Dose Pharmacokinetics of RO5424802 (clinicaltrials.gov) - Jan 19, 2014
P1, N=24, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Not yet recruiting --> Completed
- Alecensa (alectinib) / Roche
Trial completion: A Study of the Elimination, Pharmacokinetics, and Metabolism of RO5424802 (clinicaltrials.gov) - Jan 12, 2014
P1, N=6, Completed, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Completed Active, not recruiting --> Completed
- | Alecensa (alectinib) / Roche
New P1 trial: A Study Investigating the Effect of Food and Esomeprazole on the Single Oral Dose Pharmacokinetics of Alectinib (RO5424802) in Healthy Volunteers. (clinicaltrials.gov) - Dec 26, 2013
P1, N=40, Not yet recruiting, Sponsor: Hoffmann-La Roche
- | Tecentriq (atezolizumab) / Roche, Alecensa (alectinib) / Roche
New P1 trial, Combination therapy, PD(L)-1 Biomarker, Metastases: A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Dec 15, 2013
P1, N=32, Recruiting, Sponsor: Hoffmann-La Roche
- | Alecensa (alectinib) / Roche
New P1 trial: A Study of the Effects of Posaconazole on Alectinib (RO5424802) Pharmacokinetics in Healthy Volunteers (clinicaltrials.gov) - Nov 12, 2013
P1, N=23, Completed, Sponsor: Hoffmann-La Roche
- Alecensa (alectinib) / Roche
New P1 trial: A Study of the Elimination, Pharmacokinetics, and Metabolism of RO5424802 (clinicaltrials.gov) - Nov 7, 2013
P1, N=6, Completed, Sponsor: Hoffmann-La Roche
- | Alecensa (alectinib) / Roche
Enrollment closed: A Clinical Study Testing The Safety and Efficacy of CH5424802/RO5424802 in Patients With ALK Positive Non-Small Cell Lung Cancer (clinicaltrials.gov) - Oct 17, 2013
P1/2, N=36, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Alecensa (alectinib) / Roche
New P1 trial: A Study of the Effect of Multiple Doses of Rifampin on the Single Dose Pharmacokinetics of RO5424802 (clinicaltrials.gov) - Sep 10, 2013
P1, N=24, Completed, Sponsor: Hoffmann-La Roche
- |||| Alecensa (alectinib) / Roche
Enrollment open: A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Aug 12, 2013
P2, N=85, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Alecensa (alectinib) / Roche
Enrollment change: A Clinical Study Testing The Safety and Efficacy of CH5424802/RO5424802 in Patients With ALK Positive Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jun 5, 2013
P1/2, N=36, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting N=94 --> 36
- ||||| Alecensa (alectinib) / Roche
New P2 trial: A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Jun 5, 2013
P2, N=85, Recruiting, Sponsor: Hoffmann-La Roche
- ||||| Alecensa (alectinib) / Roche
New P2 trial: A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment (clinicaltrials.gov) - Feb 26, 2013
P2, N=130, Recruiting, Sponsor: Hoffmann-La Roche
- | Alecensa (alectinib) / Roche
New P1/2 trial: A Clinical Study Testing The Safety and Efficacy of CH5424802/RO5424802 in Patients With ALK Positive Non-Small Cell Lung Cancer (clinicaltrials.gov) - Apr 26, 2012
P1/2, N=36, Active, not recruiting, Sponsor: Hoffmann-La Roche